New drug duo shows promise against tough uterine cancer

NCT ID NCT03884101

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tested whether combining the immunotherapy pembrolizumab with the targeted therapy lenvatinib works better than standard chemotherapy for women with advanced or recurrent endometrial cancer. Over 800 participants received either the drug combo or chemo. The goal was to see if the combo could delay cancer growth and improve survival. The trial is now complete, and results may lead to a new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: pembrolizumab (immunotherapy) and lenvatinib (targeted therapy)
What this could lead to: If successful, this combination could offer a new first-line treatment option that helps control advanced or recurrent endometrial cancer longer than standard chemotherapy.
What could go wrong: This is a completed phase 3 trial, but results may not apply to all patients. The combination can cause side effects like high blood pressure, fatigue, and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

842 people

The number who actually took part.

Started

Apr 2019

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has Stage III, Stage IV, or recurrent, histologically-confirmed endometrial carcinoma with disease that is either measurable or nonmeasurable but radiographically apparent, per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) (note: may have received prior chemotherapy only if administered concurrently with radiation; may have received prior radiation without concurrent chemotherapy; may have received prior hormonal therapy for treatment of endometrial carcinoma, provided that it was discontinued ≥1 week prior to randomization; and may have received 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy) * Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion that was not previously irradiated, for determination of mismatch repair (MMR) status * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 7 days prior to the first dose of study intervention * Is not pregnant or breastfeeding, and is either not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to use contraception during the study and for ≥120 days after pembrolizumab, ≥30 days after lenvatinib, or ≥180 days after (chemotherapy) \[if a WOCBP, a pregnancy test will be required within 24 hours of first dose of study drug\] * Has adequately controlled blood pressure within 7 days prior to randomization * Has adequate organ function based on assessment within 7 days prior to the first dose of study intervention Exclusion Criteria: * Has carcinosarcoma (malignant mixed Műllerian tumor), endometrial leiomyosarcoma or other high grade sarcomas, or endometrial stromal sarcomas * Has a central nervous system (CNS) metastasis, unless local therapy (e.g., whole brain radiation therapy, surgery, or radiosurgery) has been completed and have discontinued use of corticosteroids for this indication for ≥4 weeks prior to starting study medication (major surgery within 3 weeks of the first dose of study drug will be exclusionary) * Has a known additional malignancy (other than endometrial carcinoma) that is progressing or has required active treatment in the last 3 years * Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib * Has a pre-existing Grade ≥3 gastrointestinal or nongastrointestinal fistula * Has radiographic evidence of major blood vessel invasion/infiltration * Has active hemoptysis (bright red blood at ≥0.5 teaspoon) within 3 weeks prior to the first dose of study intervention or tumor bleeding within 2 weeks prior to randomization * Has clinically significant cardiovascular disease within 12 months from first dose of study intervention including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction or cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability * Has any infection requiring systemic treatment * Has not recovered adequately from any toxicity and/or complications from major surgery prior to randomization * Has a known history of human immunodeficiency virus (HIV) infection (HIV test is required at screening) * Has a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (HCV) \[defined as HCV ribonucleic acid (RNA) is detected\] (hepatitis B and C testing is required at screening only when mandated by local health authority) * Has a history of (noninfectious) pneumonitis that required treatment with steroids, or has current pneumonitis * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator * Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization * Has an active autoimmune disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) * Has received prior systemic chemotherapy in any setting for the treatment of endometrial carcinoma (note: prior chemotherapy administered concurrently with radiation is permitted) * Has received prior radiotherapy within 4 weeks prior to randomization (participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis - a 2-week washout is permitted for palliative radiation to non-CNS disease and vaginal brachytherapy) * Has received prior hormonal therapy for the treatment of endometrial carcinoma within 1 week of randomization * Has received prior therapy with any treatment targeting vascular endothelial growth factor (VEGF)-directed angiogenesis, an anti-programmed cell death (PD)-1, anti-PD ligand (L)1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) * Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention * Has known intolerance to study intervention (or any of the excipients) * Has had an allogenic tissue/solid organ transplant * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial neoplasms

Contacts and locations

Locations

A.C. Camargo Cancer Center ( Site 2705)

São Paulo, 01509-900, Brazil
AZ Delta ( Site 3206)

Roeselare, West-Vlaanderen, 8800, Belgium
AZ Maria Middelares Gent ( Site 3202)

Ghent, Oost-Vlaanderen, 9000, Belgium
Akdeniz Universitesi Tıp Fakultesi ( Site 1301)

Antalya, 07070, Turkey (Türkiye)
Anhui Provincial Cancer Hospital ( Site 2509)

Hefei, Anhui, 230001, China
Arizona Oncology Associates PC- HOPE ( Site 8005)

Tucson, Arizona, 85711, United States
Asan Medical Center ( Site 1800)

Seoul, 05505, South Korea
Azienda Ospedaliera per l Emergenza Cannizzaro ( Site 0807)

Catania, 95126, Italy
BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0402)

Kelowna, British Columbia, V1Y 5L3, Canada
BC Cancer-Vancouver Center ( Site 0412)

Vancouver, British Columbia, V5Z 4E6, Canada
Baskent Universitesi Adana Uygulama ve Arastirma Hastanesi ( Site 1303)

Adana, 01120, Turkey (Türkiye)
Baskent Universitesi Ankara Hastanesi ( Site 1300)

Ankara, 06490, Turkey (Türkiye)
Beijing Cancer Hospital ( Site 2504)

Beijing, Beijing Municipality, 100142, China
Beijing Obstetrics and Gynecology Hospital Capital Medical University ( Site 2505)

Beijing, Beijing Municipality, 100032, China
Bialostockie Centrum Onkologii ( Site 1005)

Bialystok, Podlaskie Voivodeship, 15-027, Poland
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0414)

Montreal, Quebec, H1T 2M4, Canada
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0417)

Sherbrooke, Quebec, J1H 5N4, Canada
Caritas-Krankenhaus St. Josef Regensburg ( Site 0613)

Regensburg, Bavaria, 93053, Germany
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0411)

Montreal, Quebec, H2X 3E4, Canada
Centro Estatal de Cancerologia de Chihuahua ( Site 3101)

Chihuahua City, 31000, Mexico
Centro Oncologico Internacional. SEDNA ( Site 3106)

Mexico City, 04700, Mexico
Centro Oncologico Riojano Integral ( Site 2605)

La Rioja, 5300, Argentina
Centro de Investigacion Clinica Gramel ( Site 3107)

Mexico City, 03720, Mexico
Centrum Onkologii Instytut im. MSC Oddział w Gliwicach ( Site 1017)

Gliwice, Silesian Voivodeship, 44-102, Poland
Chaim Sheba Medical Center ( Site 0707)

Ramat Gan, 5262000, Israel
Charite Universitaetsmedizin Berlin ( Site 0609)

Berlin, 13353, Germany
China Medical University Hospital ( Site 1903)

Taichung, 404, Taiwan
Chongqing Cancer Hospital ( Site 2513)

Chongqing, Chongqing Municipality, 400030, China
Chris OBrien Lifehouse ( Site 1605)

Camperdown, New South Wales, 2050, Australia
Churchill Hospital ( Site 1406)

Oxford, Oxfordshire, OX3 7LE, United Kingdom
City Clinical Hosp.4 of DCC ( Site 1501)

Dnipro, Dnipropetrovsk Oblast, 49102, Ukraine
Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 2706)

São Paulo, 01317-001, Brazil
Clinical oncology dispensary of Dnipro ( Site 1512)

Dnipro, Dnipropetrovsk Oblast, 49055, Ukraine
Cliniques Universitaires Saint-Luc ( Site 3203)

Brussels, Bruxelles-Capitale, Region de, 1200, Belgium
Communal non profit enterprise Regional Clinical Oncology Center ( Site 1509)

Kharkiv, Kharkiv Oblast, 61070, Ukraine
Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 1202)

A Coruña, La Coruna, 15006, Spain
Consultorio Dentro de la Torre Medica Dalinde Oncologia Medica ( Site 3108)

Mexico City, 06760, Mexico
Cork University Hospital ( Site 1400)

Cork, T12 YE02, Ireland
Cross Cancer Institute ( Site 0408)

Edmonton, Alberta, T6G 1Z2, Canada
Cukurova Uni. Tip Fakultesi ( Site 1302)

Adana, 01330, Turkey (Türkiye)
Edith Wolfson Medical Center ( Site 0703)

Holon, Tell Abib, 5822012, Israel
Ehime University Hospital ( Site 2413)

Tōon, Ehime, 791-0295, Japan
Epworth Freemasons Hospital ( Site 1609)

Melbourne, Victoria, 3002, Australia
FSBI-FRCC of Special Types Med. Care and Technologies FMBA of Russia ( Site 1102)

Moscow, Moscow, 115682, Russia
Faculdade de Medicina da Universidade Federal de Minas Gerais ( Site 2708)

Belo Horizonte, Minas Gerais, 30130-100, Brazil
Fudan University Shanghai Cancer Center ( Site 2500)

Shanghai, Shanghai Municipality, 200032, China
Gazi Universitesi Tip Fakultesi ( Site 1308)

Ankara, 05600, Turkey (Türkiye)
Georgia Cancer Center at Augusta University ( Site 0222)

Augusta, Georgia, 30912, United States
Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 1511)

Kharkiv, Kharkiv Oblast, 61024, Ukraine
Guang Xi Tumour Hospital, Department of Chemotherapy ( Site 2517)

Nanning, Guangxi, 530021, China
Gunma Prefectural Cancer Center ( Site 2404)

Ōta, Gunma, 373-8550, Japan
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0623)

Wiesbaden, Hesse, 65199, Germany
Holy Name Medical Center ( Site 0235)

Teaneck, New Jersey, 07666, United States
Hospital Aleman ( Site 2600)

Buenos Aires, C1118AAT, Argentina
Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 2702)

Goiânia, Goiás, 74605-070, Brazil
Hospital Clinico San Carlos ( Site 1209)

Madrid, 28040, Spain
Hospital General Universitario de Valencia ( Site 1203)

Valencia, Valenciana, Comunitat, 46014, Spain
Hospital Italiano de Buenos Aires ( Site 2603)

Buenos Aires, C1199ABB, Argentina
Hospital Italiano de La Plata ( Site 2601)

La Plata, Buenos Aires, B1900AXI, Argentina
Hospital Materno Infantil [Malaga, Spain] ( Site 1208)

Málaga, 29011, Spain
Hospital San Lucas Cardiologica del Sureste ( Site 3103)

Tuxtla Gutiérrez, Chiapas, 29090, Mexico
Hospital Universitario Reina Sofia ( Site 1207)

Córdoba, 14004, Spain
Hospital de Base de Sao Jose de Rio Preto ( Site 2704)

São José do Rio Preto, São Paulo, 15090-000, Brazil
Hospital de Caridade de Ijui ( Site 2712)

Ijuí, Rio Grande do Sul, 98700-000, Brazil
Hubei Cancer Hospital ( Site 2510)

Wuhan, Hubei, 430079, China
Hyogo Cancer Center ( Site 2414)

Akashi, Hyōgo, 673-8558, Japan
I CAN Oncology SA de SV ( Site 3102)

Monterrey, Nuevo León, 64710, Mexico
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 2607)

Caba, Buenos Aires, C1012AAR, Argentina
IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0801)

Bari, 70124, Italy
Institut Catala d Oncologia Badalona ( Site 1201)

Badalona, Barcelona, 08916, Spain
Instituto Nacional do Cancer II ( Site 2707)

Rio de Janeiro, 20220-410, Brazil
Instituto Valenciano de Oncologia - IVO ( Site 1205)

Valencia, Valenciana, Comunitat, 46009, Spain
Instituto de Investigaciones Clinicas Mar del Plata ( Site 2606)

Mar del Plata, Buenos Aires, B7600FZO, Argentina
Instituto do Cancer do Ceara ( Site 2703)

Fortaleza, Ceará, 60430-230, Brazil
Instytut Centrum Zdrowia Matki Polki ( Site 1020)

Lodz, Łódź Voivodeship, 93-338, Poland
Istituto Nazionale Tumori Fondazione Pascale ( Site 0808)

Naples, 80131, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0800)

Meldola, Emilia-Romagna, 47014, Italy
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0226)

Hackensack, New Jersey, 07601, United States
Juravinski Cancer Centre ( Site 0406)

Hamilton, Ontario, L8V 1C3, Canada
Keio University Hospital ( Site 2411)

Tokyo, 160-8582, Japan
Khmelnitskiy Regional Onkology Dispensary ( Site 1513)

Khmelnitskiy, Khmelnytskyi Oblast, 29009, Ukraine
Kingston Health Sciences Centre ( Site 0401)

Kingston, Ontario, K7L 2V7, Canada
Krasnoyarsk Regional Clinical oncology dispensary ( Site 1118)

Krasnoyarsk, Krasnoyarsk Krai, 660133, Russia
Kurume University Hospital ( Site 2403)

Kurume, Fukuoka, 830-0011, Japan
Kyiv City Clinical Oncology Centre ( Site 1505)

Kyiv, 03115, Ukraine
Kyorin University Hospital ( Site 2402)

Mitaka, Tokyo, 181-8611, Japan
Legacy Salmon Creek Medical Center ( Site 0253)

Vancouver, Washington, 98686, United States
Linkou Chang Gung Memorial Hospital ( Site 1901)

Taoyuan, 333, Taiwan
MI Odessa Regional Oncological Centre ( Site 1504)

Odesa, Odesa Oblast, 65055, Ukraine
MI Precarpathian Clinical Oncology Center ( Site 1503)

Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine
MSKCC-Bergen ( Site 0276)

Montvale, New Jersey, 07645, United States
Maine Medical Partners ( Site 0217)

Scarborough, Maine, 04074, United States
Mater Misericordiae Ltd ( Site 1608)

South Brisbane, Queensland, 4101, Australia
McGill University Health Centre ( Site 0404)

Montreal, Quebec, H4A 3J1, Canada
Medical Center Asklepion LLC ( Site 1514)

Khodosovka, Kyivska Oblast, 08173, Ukraine
Medical Oncology Ospedale San Donato ( Site 0812)

Arezzo, 52100, Italy
Medical Rehabilitation Center ( Site 1101)

Moscow, Moscow, 125367, Russia
Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 1507)

Kyiv, Kyivska Oblast, 03126, Ukraine
Medizinische Universitat Innsbruck ( Site 3302)

Innsbruck, Tyrol, 6020, Austria
Medizinische Universitat Wien ( Site 3300)

Vienna, State of Vienna, 1090, Austria
Meir Medical Center ( Site 0702)

Kfar Saba, Central District, 4428132, Israel
Memorial Sloan Kettering Cancer Center ( Site 0246)

New York, New York, 10022, United States
Memorial Sloan Kettering Cancer Center - Nassau ( Site 0275)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Cancer Center - West Harrison ( Site 0274)

Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0273)

Middletown, New Jersey, 07748, United States
Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 0268)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan-Kettering Cancer Center at Commack ( Site 0267)

Commack, New York, 11725, United States
Minnesota Oncology Hematology, PA ( Site 8003)

Minneapolis, Minnesota, 55404, United States
Monash Health ( Site 1606)

Clayton, Victoria, 3168, Australia
Mount Vernon Cancer Centre ( Site 1409)

Northwood, London, City of, HA6 2RN, United Kingdom
Nanjing Maternity and Child Health Care Hospital ( Site 2508)

Nanjing, Jiangsu, 210011, China
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1009)

Warsaw, Masovian Voivodeship, 02-781, Poland
National Cancer Institute of the MoH of Ukraine ( Site 1510)

Kyiv, Kyivska Oblast, 03022, Ukraine
National Defense Medical College Hospital ( Site 2418)

Tokorozawa, Saitama, 359-8513, Japan
National Hospital Organization Hokkaido Cancer Center ( Site 2408)

Sapporo, Hokkaido, 003-0804, Japan
National Hospital Organization Kyushu Cancer Center ( Site 2405)

Fukuoka, 811-1395, Japan
National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 1103)

Saint Petersburg, Sankt-Peterburg, 197758, Russia
National Taiwan University Hospital ( Site 1904)

Taipei, 10002, Taiwan
Niigata Cancer Center Hospital ( Site 2415)

Niigata, 951-8566, Japan
Nippon Medical School Musashi Kosugi Hospital ( Site 2417)

Kawasaki, Kanagawa, 211-8533, Japan
Northern Centre for Cancer Care ( Site 1408)

Newcastle upon Tyne, NE7 7DN, United Kingdom
Obstetrics and Gynecology Hosp. Fudan University ( Site 2503)

Shanghai, Shanghai Municipality, 200090, China
Osaka International Cancer Institute ( Site 2409)

Osaka, 541-8567, Japan
Ospedale Antonio Perrino ( Site 0806)

Brindisi, 72100, Italy
Ospedale Policlinico S. Orsola-Malpighi ( Site 0803)

Bologna, 40138, Italy
Ospedale dell Angelo ( Site 0810)

Mestre, Venezia, 30174, Italy
Parc de Salut Mar ( Site 1200)

Barcelona, 08003, Spain
Parkland Health & Hospital System ( Site 0272)

Dallas, Texas, 75235, United States
Peking Union Medical College Hospital ( Site 2501)

Beijing, Beijing Municipality, 100032, China
Policlinico Universitario Agostino Gemelli ( Site 0805)

Rome, Roma, 00168, Italy
Prince of Wales Hospital [Australia] ( Site 1603)

Randwick, New South Wales, 2031, Australia
Princess Margaret Cancer Centre ( Site 0409)

Toronto, Ontario, M5G 2M9, Canada
Railway Hospital of OJSC ( Site 1122)

Saint Petersburg, Sankt-Peterburg, 195271, Russia
Rambam Medical Center ( Site 0700)

Haifa, 3525408, Israel
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 2713)

São Paulo, 01321-001, Brazil
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1108)

Kazan', Tatarstan, Respublika, 420029, Russia
Roger Maris Cancer Center ( Site 0277)

Fargo, North Dakota, 58102, United States
Royal North Shore Hospital ( Site 1600)

St Leonards, New South Wales, 2065, Australia
Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1100)

Moscow, Moscow, 115478, Russia
SPb SBHI City Clinical Oncological Dispensary ( Site 1104)

Saint Petersburg, Sankt-Peterburg, 198255, Russia
Saitama Cancer Center ( Site 2406)

Kitaadachi-gun, Saitama, 362-0806, Japan
Saitama Medical University International Medical Center ( Site 2410)

Hidaka, Saitama, 350-1298, Japan
Samara Regional Clinical Oncology Center ( Site 1117)

Samara, Samara Oblast, 443031, Russia
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1008)

Lublin, Lower Silesian Voivodeship, 20-081, Poland
Samsung Medical Center ( Site 1803)

Seoul, 06351, South Korea
Sanford Cancer Center Oncology Clinic ( Site 0205)

Sioux Falls, South Dakota, 57104, United States
Seoul National University Bundang Hospital ( Site 1802)

Seongnam-si, Kyonggi-do, 13620, South Korea
Seoul National University Hospital ( Site 1801)

Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System ( Site 1804)

Seoul, 03722, South Korea
Showa University Hospital ( Site 2419)

Tokyo, 142-8666, Japan
Siberian State Medical University ( Site 1121)

Tomsk, Tomsk Oblast, 634028, Russia
Sir Charles Gairdner Hospital ( Site 1604)

Nedlands, Western Australia, 6009, Australia
Smilow Cancer Hospital at Yale New Haven ( Site 0202)

New Haven, Connecticut, 06511, United States
St James Hospital ( Site 1401)

Dublin, Dublin 8, Ireland
St. Marianna University School of Medicine Hospital ( Site 2416)

Kawasaki, Kanagawa, 216-8511, Japan
St.Petersburg Clinical Hospital RAS ( Site 1124)

Saint Petersburg, Sankt-Peterburg, 194017, Russia
Sunnybrook Research Institute ( Site 0410)

Toronto, Ontario, M4N 3M5, Canada
Szpital Kliniczny im Ks Anny Mazowieckiej ( Site 1011)

Warsaw, Masovian Voivodeship, 00-315, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 1019)

Krakow, Lesser Poland Voivodeship, 31-826, Poland
Taichung Veterans General Hospital ( Site 1902)

Taichung, 40705, Taiwan
Taipei Veterans General Hospital ( Site 1900)

Taipei, 11217, Taiwan
Texas Oncology-The Woodlands ( Site 8000)

The Woodlands, Texas, 77380, United States
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0206)

New York, New York, 10011, United States
The Cancer Institute Hospital of JFCR ( Site 2401)

Tokyo, 135-8550, Japan
The Credit Valley Hospital ( Site 0403)

Mississauga, Ontario, L5M 2N1, Canada
The Crown Princess Mary Cancer Centre - Westmead Hospital ( Site 1602)

Westmead, New South Wales, 2145, Australia
The First Affiliated Hospital of Xinjiang Medical University ( Site 2515)

Ürümqi, Xinjiang, 830054, China
The First Affiliated Hospital.Sun Yat-sen University ( Site 2507)

Guangzhou, Guangdong, 510080, China
The James Cook University Hospital ( Site 1403)

Middlesbrough, TS4 3BW, United Kingdom
The first affiliated Hospital of Xi an Jiaotong University ( Site 2502)

Xi'an, Shaanxi, 710061, China
UCLA Hematology and Oncology Clinic (Westwood) ( Site 0233)

Los Angeles, California, 90095, United States
UCLH NHS Foundation Trust ( Site 1405)

London, London, City of, NW1 2PG, United Kingdom
UZ Leuven ( Site 3200)

Leuven, Antwerpen, 3000, Belgium
UZA University Hospital Antwerp ( Site 3204)

Edegem, Antwerpen, 2650, Belgium
Uludag Universitesi Tip Fakultesi ( Site 1307)

Bursa, 16059, Turkey (Türkiye)
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 2701)

Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Universitaetsklinikum Essen ( Site 0616)

Essen, North Rhine-Westphalia, 45147, Germany
Universitaetsklinikum Jena ( Site 0612)

Jena, Thuringia, 07747, Germany
Universitaetsklinikum Muenster ( Site 0615)

Münster, Baden-Wurttemberg, 48149, Germany
Universitaetsmedizin Mannheim. Klinik fuer Kinder und Jugendmedizin ( Site 0622)

Mannheim, Baden-Wurttemberg, 68167, Germany
Universitatsklinik fuer Frauenheilkunde und Geburtshilfe ( Site 3301)

Graz, Styria, 8036, Austria
University of Colorado Cancer Center ( Site 0204)

Aurora, Colorado, 80045, United States
University of Miami Health System ( Site 0249)

Miami, Florida, 33136, United States
University of North Carolina- Chapel Hill ( Site 0254)

Chapel Hill, North Carolina, 27599, United States
University of Rochester ( Site 0238)

Rochester, New York, 14642, United States
University of South Alabama, Mitchell Cancer Institute ( Site 0245)

Mobile, Alabama, 36604, United States
University of Texas Southwestern Medical Center ( Site 0264)

Dallas, Texas, 75390-9015, United States
University of the Ryukyus Hospital ( Site 2412)

Nakagami-gun, Okinawa, 903-0215, Japan
Western General Hospital ( Site 1411)

Edinburgh, Edinburgh, City of, EH4 2XU, United Kingdom
Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 1004)

Poznan, Greater Poland Voivodeship, 61-866, Poland
Willamette Valley Cancer Institute and Research Center ( Site 8004)

Eugene, Oregon, 97401, United States
Women s Hospital School of Medicine Zhejiang University ( Site 2511)

Hangzhou, Zhejiang, 310006, China
Women's Cancer Care ( Site 0208)

Covington, Louisiana, 70433, United States
Xiangya Hospital Central-South University ( Site 2512)

Changsha, Hunan, 410008, China
Zhejiang Cancer Hospital ( Site 2506)

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.